Difference between revisions of "Finasteride (Proscar)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
m |
||
| Line 11: | Line 11: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Antiandrogens]] | ||
| + | [[Category:5 alpha-reductase inhibitors]] | ||
| + | [[Category:Prostate cancer medications]] | ||
Revision as of 17:00, 13 January 2014
General information
Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Specifically and competitively inhibits Type II 5α-reductase by forming a stable enzyme-drug complex.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]